Cambridge Nutritional Sciences PLC Notice of Results and Investor Presentation (2564S)
November 06 2023 - 2:00AM
UK Regulatory
TIDMCNSL
RNS Number : 2564S
Cambridge Nutritional Sciences PLC
06 November 2023
Cambridge Nutritional Sciences plc
(the 'Company' or 'CNS')
Notice of Results and Investor Presentation
Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist
medical diagnostics company focused on promoting a personalised and
functional approach to health and nutrition, confirms it will issue
its Half Year results for the six months ended 30 September 2023 on
Thursday 23 November 2023.
Investor presentation
Jag Grewal, CEO and Simon Douglas, Chairman will provide a live
presentation relating to the Half Year Results via the Investor
Meet Company platform on Thursday 23 November 2023 at 16:30
BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Cambridge Nutritional Sciences plc via:
https://www.investormeetcompany.com/cambridge-nutritional-sciences-plc/register-investor
Investors who already follow Cambridge Nutritional Sciences plc
on the Investor Meet Company platform will automatically be
invited.
Contacts:
Cambridge Nutritional Sciences plc www.cnsplc.com
Jag Grewal, Chief Executive Officer via Walbrook PR
Cavendish Capital Markets Limited Tel: 020 7220 0500
Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or CNS@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502 558 258
About Cambridge Nutritional Sciences plc
Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist
medical diagnostics company focused on industry-leading Health and
Nutrition products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFSAFWEEDSEIF
(END) Dow Jones Newswires
November 06, 2023 02:00 ET (07:00 GMT)
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Aug 2023 to Aug 2024